Please disable your Ad Blocker to better interact with this website.

And This Is The Other Half Of What It’s All About – Vaccine Execs Rake In $1 Billion In Stock Sales As Positive Headlines Boost Shares

Written by:

Published on: July 27, 2020

Of course, the first half is about control, and we’re seeing the second half play out as well, which is a very real part of fascism:  Money.  However, don’t worry, it’s just a bunch of “Trump haters” that are pointing this out, right?  Wrong.  The point is that Trump is overseeing Operation Warp Speed, designed to make vaccines more profitable and even less safe than they have been in years.  Already it’s being reported that vaccine executives, you know those guys who can’t be sued for making products that have harmed, injured and even killed other people, are raking in more than a billion dollars, and they haven’t even created a vaccine yet!  And it isn’t just the politicians aiding them.  It’s the useful idiots in the media.

Tyler Durden at Zero Hedge has the story.

With the race to find a vaccine for COVID-19 in full effect, biotech executives and other insiders from at least 11 companies have made hand over fist – raking in over $1 billion in stock sales after announcing positive developments, according to the New York Times.

In some cases, company insiders are profiting from regularly scheduled compensation or automatic stock trades. But in other situations, senior officials appear to be pouncing on opportunities to cash out while their stock prices are sky high. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. -NYT

Trending: I Had Aggressive Cancer, But Was Healed Naturally Within 5 Months. Here's What I Did.

In May, we noted that insiders at Moderna cashed out on some $30 million in options – while CEO Stephane Bancel has become a billionaire.

Moderna CEO Stéphane Bancel

The company’s market value is now nearly $30 billion thanks to a stream of positive press releases, while insiders have sold around $248 million altogether since January – most of it coming following an April announcement that the company had been selected to receive federal funding to support their efforts.

The Times highlights another case; South San Francisco-based Vaxart, which was selected by the US government to participate in a federal initiative to quickly produce COVID-19 treatments known as Operation Warp Speed.

Vaxart’s shares soared. Company insiders, who weeks earlier had received stock options worth a few million dollars, saw the value of those awards increase sixfold. And a hedge fund that partly controlled the company walked away with more than $200 million in instant profits.

Meanwhile, companies such as Vaxart are allegedly using their inclusion in Operation Warp Speed as marketing ploys.

For example, the headline on Vaxart’s news release declared: “Vaxart’s Covid-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed.” But the reality is more complex.

Vaxart’s vaccine candidate was included in a trial on primates that a federal agency was organizing in conjunction with Operation Warp Speed. But Vaxart is not among the companies selected to receive significant financial support from Warp Speed to produce hundreds of millions of vaccine doses.

Michael R. Caputo, the US Department of Health and Human Services’ assistant secretary for public affairs said the agency “has entered into funding agreements with certain vaccine manufacturers, and we are negotiating with others,” but added “Neither is the case with Vaxart.”

“Vaxart’s vaccine candidate was selected to participate in preliminary U.S. government studies to determine potential areas for possible Operation Warp Speed partnership and support. At this time, those studies are ongoing, and no determinations have been made,” he added.

CEO Andrei Floroiu – who received stock options worth approximately $4.3 million in June (and worth $28 million weeks later) – defended his company, saying in a Friday statement “Vaxart abides by good corporate governance guidelines and policies and makes decisions in accordance with the best interests of the company and its shareholders,” adding “We believe that Vaxart’s Covid-19 vaccine is the most exciting one in O.W.S. because it is the only oral vaccine (a pill) in O.W.S.”

Andrei Floroiu, the chief executive of Vaxart, received stock options worth about $4.3 million in June. A month later, they were worth more than $28 million.Credit…Will Ragozzino/Patrick McMullan

While ‘fortunately timed’ stock sales are typically legal, they can create the appearance of malfeasance and profiteering from insider information.

It is inappropriate for drug company executives to cash in on a crisis,” said Ben Wakana, executive director of nonprofit advocacy group, Patients for Affordable Drugs. “Every day, Americans wake up and make sacrifices during this pandemic. Drug companies see this as a payday.”

Executives at a long list of companies have reaped seven- or eight-figure profits thanks to their work on coronavirus vaccines and treatments.

Shares of Regeneron, a biotech company in Tarrytown, N.Y., have climbed nearly 80 percent since early February, when it announced a collaboration with the Department of Health and Human Services to develop a Covid-19 treatment. Since then, the company’s top executives and board members have sold nearly $700 million in stock. The chief executive, Leonard Schleifer, sold $178 million of shares on a single day in May.

Alexandra Bowie, a spokeswoman for Regeneron, said most of those sales had been scheduled in advance through programs that automatically sell executives’ shares if the stock hits a certain price. –NYT

Meanwhile, executives and board members for Emergent BioSolutions, Quidel and Luminex have offloaded a combined $85 million in shares following positive announcements regarding vaccines, testing solutions or treatments according to the Times.

In April, Gaithersburg, MD-based Novavax issued a slew of stock awards to all employees when the stock was below $24 “in acknowledgment of the extraordinary work of our employees to implement a new vaccine program.” Four senior executives – including CEO Stanley Erck, received awards worth under $20 million at the time.

Now, with shares over $135, the four execs’ stock options are worth over $100 million on paper. As long as the company achieves a vaccine testing milestone, which they expect to hit soon, they’ll be able to use the options to buy discounted shares as early as 2021 regardless of whether or not they are successful in developing a vaccine.

Read the rest of the report here.

What is clear in all of this is there is a lot of money to be made in the hoax that is coronavirus/COVID-19.  Sadly, people have been so dumbed down that they don’t even consider the fact that not one vaccine has been proven to prevent any disease, but they have been proven to cause harm and death.  Meanwhile, those creating this snake oil have immunity from lawsuits by those they harm, and quietly pay off their victims, at least those that are allowed to be paid off.  Many get absolutely nothing.

Become an insider!

Sign up to get breaking alerts from Sons of Liberty Media.

Don't forget to like SonsOfLibertyMedia.com on Facebook, Google+, & Twitter.
The opinions expressed in each article are the opinions of the author alone and do not necessarily reflect those of SonsOfLibertyMedia.com.

 

Join the conversation!

We have no tolerance for comments containing violence, racism, vulgarity, profanity, all caps, or discourteous behavior. Thank you for partnering with us to maintain a courteous and useful public environment where we can engage in reasonable discourse.

Trending on The Sons of Liberty Media

Send this to a friend